BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 6177458)

  • 1. Natural killer cell function in trisomy-21 (Down's syndrome).
    Nurmi T; Huttunen K; Lassila O; Henttonen M; Säkkinen A; Linna SL; Tiilikainen A
    Clin Exp Immunol; 1982 Mar; 47(3):735-41. PubMed ID: 6177458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of human natural killing. II. Protective effect of interferon on NK cells from suppression by PGE2.
    Leung KH; Koren HS
    J Immunol; 1982 Oct; 129(4):1742-7. PubMed ID: 6180022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of natural killer cytotoxicity by recombinant alpha interferons. Augmentation by IFN-alpha 7, an interferon similar to IFN-alpha J.
    Platsoucas CD; Fox FE; Oleszak E; Fong K; Nanno M; Ioannides CG; Trotta PP
    Anticancer Res; 1989; 9(4):849-58. PubMed ID: 2817813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monocyte-mediated augmentation of human natural killer cell activity: conditions, monocyte and effector cell characteristics.
    Bloom ET; Babbitt JT; Kawakami K
    J Immunol; 1986 Jul; 137(1):172-8. PubMed ID: 3711665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
    Colotta F; Peri G; Villa A; Mantovani A
    J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell function of human neonatal lymphocytes.
    Uksila J; Lassila O; Hirvonen T
    Clin Exp Immunol; 1982 Jun; 48(3):649-54. PubMed ID: 6180853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer activity of human lymphocytes against colon cancer cells.
    Helms RA; Bull DM
    Gastroenterology; 1980 Apr; 78(4):738-44. PubMed ID: 7353760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of macrophage in in vitro augmentation of rat, mouse, and human natural killer activities.
    Reynolds CW; Brunda MJ; Holden HT; Herberman RB
    J Natl Cancer Inst; 1981 May; 66(5):837-42. PubMed ID: 6164813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of in vitro maintenance and interferon-mediated augmentation of natural killer cell activity by adherent peritoneal cells from normal mice.
    Brunda MJ; Taramelli D; Holden HT; Varesio L
    J Immunol; 1983 Apr; 130(4):1974-9. PubMed ID: 6187831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of D-glucosamine on human natural killer activity in vitro.
    Matheson DS; Green BJ; Friedman SJ
    J Biol Response Mod; 1984 Aug; 3(4):445-53. PubMed ID: 6207272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrasting effects of lactoferrin on human lymphocyte and monocyte natural killer activity and antibody-dependent cell-mediated cytotoxicity.
    Nishiya K; Horwitz DA
    J Immunol; 1982 Dec; 129(6):2519-23. PubMed ID: 7142699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of sera of breast cancer patients on NK cell activity].
    Konjević G; Spuzić I
    Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of interferon in augmentation of natural and antibody-dependent cell-mediated cytotoxicity.
    Herberman RB; Djeu JY; Ortaldo JR; Holden HT; West WH; Bonnard GD
    Cancer Treat Rep; 1978 Nov; 62(11):1893-6. PubMed ID: 728907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
    Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
    Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual effects of cytokines in regulation of MHC-unrestricted cell mediated cytotoxicity.
    Reiter Z
    Crit Rev Immunol; 1993; 13(1):1-34. PubMed ID: 8466640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
    Edwards BS; Hawkins MJ; Borden EC
    Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer activity and antibody-dependent cellular cytotoxicity in patients with non-Hodgkin's lymphoma.
    Metha BA; Advani SH; Nadkarni SJ
    Neoplasma; 1988; 35(1):61-8. PubMed ID: 3352838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor.
    Benczur M; Petrányl GG; Pálffy G; Varga M; Tálas M; Kotsy B; Földes I; Hollán SR
    Clin Exp Immunol; 1980 Mar; 39(3):657-62. PubMed ID: 6155232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.